Clinical Evaluation of CEM-guided Biopsy

CompletedOBSERVATIONAL
Enrollment

66

Participants

Timeline

Start Date

October 8, 2019

Primary Completion Date

September 27, 2021

Study Completion Date

October 6, 2021

Conditions
Contrast Enhanced Mammography-guided Biopsy
Interventions
DEVICE

CEM-guided biopsy

"The evaluation population consists of adult women, presenting with clinical indication for a breast biopsy procedure after a positive abnormal CEM or MRI examination (with no clear ultrasound or mammography correlation) and considered eligible for this procedure as per standard of care.~Eligible subjects undergo the clinically indicated breast biopsy procedure using the Pristina Serena Bright ® CEM-guided biopsy. Region of interest location is determined by using stereotactic pairs of CEM images after injection of iodinated contrast media. All necessary equipment and instrumentation, medications, or other devices required to complete the subject's clinically indicated procedure shall be used and are not expected to be influenced by evaluation participation."

Trial Locations (1)

08003

Hospital del Mar - Parc de Salut Mar, Barcelona

All Listed Sponsors
collaborator

General Electric

INDUSTRY

lead

Parc de Salut Mar

OTHER

NCT05250674 - Clinical Evaluation of CEM-guided Biopsy | Biotech Hunter | Biotech Hunter